Nanorobotics designed to redefine pancreatic cancer care

| Earlier molecular insight
| Greater precision
| More targeted care

Earlier molecular insight when it matters

THE GAP

Pancreatic cancer is difficult to diagnose early. Once cancer is suspected, patients can move through multiple investigations before clinicians have enough information to determine the right next step. Imaging, blood tests, endoscopic procedures and tissue sampling remain important, but the pathway can be sequential, time-consuming and invasive, leaving patients, families and care teams with ongoing uncertainty.

Explore Our Technology

Partner with Us

OUR APPROACH

NanoCube Health is developing a nanosensing and nanomotor platform with the aim of providing biopsy-like molecular insight without conventional tissue sampling.

By bringing molecular information closer to the disease itself, the platform is being developed to provide useful biological insight earlier in the diagnostic pathway, with the aim of improving diagnostic confidence, reducing avoidable sequential investigations and supporting clearer, more timely clinical decisions.

The same targeted platform is also being evaluated for drug delivery in pancreatic cancer, creating potential for therapeutic applications.

The platform is progressing through preclinical validation, with future clinical studies required to establish diagnostic performance and therapeutic benefit.

Bringing molecular sensing to the disease itself

NanoCube’s platform is designed to interact with disease-associated biology in vivo, generate molecular signals close to their source and enable those signals to be read externally.

Website - Target, Sense, Interpret, Deli

One platform. Two paths
to patient impact

Website - Diagnostics and Therapeutics Overview.png

Building the evidence

Preclinical work has demonstrated target binding, measurable signal generation and nanomotor behaviour, with advanced 3D pancreatic cancer model work supporting progression into in vivo validation.